Citi analyst Patrick Donnelly raised the firm’s price target on Waters to $300 from $265 and keeps a Neutral rating on the shares. Heading into 2024, the analyst sees investor appetite across the life science tools space as “remaining light” following a challenging year with consistent downwards earnings revisions. The industry has seen a reset that will continue into next year driven by headwinds across biopharma with notable weakness in bioprocessing, instrumentation, and lingering challenges in China, the analyst tells investors in a research note. Going into next year, Citi sees modest downside to 2024 estimates in tools broadly, and names Bruker (BRKR) its top pick in tools, Qiagen (QGEN) its top pick in diagnostics, and Fortrea Holding (FTRE) its top pick in labs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WAT:
- Waters inaugurates new Global Capability Center in India
- Early notable gainers among liquid option names on November 21st
- Oracle upgraded, Southwest downgraded: Wall Street’s top analyst calls
- Barclays downgrades Waters to Underweight on instrument downturn
- Waters downgraded to Underweight from Equal Weight at Barclays